1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Testosterone |
| brand | String | AndroGel, Testim, Axiron, Fortesta (gels); Androderm (patch); Aveed (IM); Striant (buccal); Natesto (nasal); Jatenzo, Tlando (oral undecanoate) |
| structure | File | |
| classes | List of String, delimiter: , | Androgen / Anabolic Steroid |
| mechanism | String | Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT. |
| uses | String | '"`UNIQ--vote-00000758-QINU`"', '"`UNIQ--vote-00000759-QINU`"', '"`UNIQ--vote-0000075A-QINU`"' |
| starting_dose | String | Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d. |
| preparations | String | Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets |
| fda_max | String | Formulation-dependent |
| pill_id | Text | |
| routes | List of String, delimiter: , | Topical (gel/patch) • IM • buccal • nasal • oral (undecanoate only) |
| onset | String | Hours (transdermal); days (IM esters) |
| duration | String | Hours (nasal); ~24 h (gel/patch); 1–2 weeks (cypionate/enanthate IM); ~10 weeks (undecanoate IM) |
| halflife | String | Highly variable by formulation; native T is hours |
| bioavailability | String | Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass) |
| pregnancy | String | Category X, contraindicated; teratogenic (virilization of female fetus) |
| legal | String | Schedule III (DEA, US) |
